Prostate cancer patients receiving androgen-deprivation therapies shown to be at lower risk from COVID-19

Share :
Published: 7 May 2020
Views: 1583
Prof Andrea Alimonti - Università della Svizzera Italiana, Bellinzona, Switzerland

Prof Andrea Alimonti speaks to ecancer about his research on how androgen-deprivation therapy (ADT) could protect men from COVID-19.

The study suggests that prostate cancer patients receiving ADT were less likely to be infected by COVID-19, and those who were infected were less likely to experience severe complications.

Prof Alimonti explains that their research followed on from findings showing that protein TMPRSS2 - which is regulated by the androgen receptor - helps the COVID-19 virus to bind to human cells. He goes on to discuss the potential applications of these findings on future research and patient care.

While coronavirus cases are beginning to decline in some countries, Prof Alimonti stresses that it is still important to research the connection between ADT and COVID-19 so that there may be implementable results to protect vulnerable men in the event of a second wave of infections.

Read more about the results here.